[A new method for managing epistaxis in Osler's disease (author's transl)].
We describe a new method for successful management of epistaxis in patients with hereditary hemorrhagic telangiectasias. By so doing, even pulmonary arteriovenous fistulas and gastrointestinal hemorrhages can be successfully managed. During a four year period, 14 patients were treated with an oral contraceptive preparation which combined a reduced dosage of estrogen and progesterone. With this therapy, 11 patients stopped bleeding while 3 responded with significant improvement. We believe that this effect on bleeding by the hormone therapy is a sign of an abnormal increase of specific hormone requirements in patients with Osler's disease.
D000328:Adult; D003277:Contraceptives, Oral, Combined; D004844:Epistaxis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008656:Mestranol / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009641:Norethynodrel / Q000009:adverse effects / Q000627:therapeutic use*; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy*
D003277:Contraceptives, Oral, Combined; C008124:Infecundin; D009641:Norethynodrel; D008656:Mestranol
Neue therapeutische Möglichkeiten bei M. Osler.